Generate Biomedicines is trading 10.22% higher at $14.56 on October 28, alongside broader biotech strength; no source confirms a specific driver for the move. - XBI is up 2.18%, supporting a possible sector contribution but not explaining the larger stock gain. - On October 27, the company highlighted research with Anthropic’s Claude describing laboratory tests of a redesigned CAR T-cell receptor. The results are early-stage and have not been tested in animals or humans.